Azaphen
(Synonyms: Azafen; Pipofezin hydrochloride; Pipofezine hydrochloride)
1 Cited Publications
Customer Review
Based on 1 publication(s) in Google Scholar
Azaphen (Pipofezin) is an orally active serotonin reuptake inhibitor. Azaphen potentiates sympathomimetic compound effects. Azaphen can be used for the research of depressive states.
For research use only. We do not sell to patients.
- CAS No.: 24853-80-3
- Formula: C16H21Cl2N5O
- Molecular Weight:370.28
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Azaphen
More
Biological Activity
Description
In Vivo
Azaphen (10-25 mg/kg; single dose) significantly prolongs Phenamine (HY-W016477)-induced stereotypic behavioral reactions in white rats, with mean durations increased to 105 min and 147 min, respectively[1].
Azaphen (25-50 mg/kg; s.c.; single dose) significantly increases the group toxicity of Phenamine in white mice, inducing up to 95% mortality when combined with 10 mg/kg Phenamine, while also enhancing Phenamine-induced motor activity and hyperthermia[1].
Azaphen (25-50 mg/kg; s.c.; single dose) antagonizes Reserpine (HY-N0480)-induced depression effects in white mice, reducing blepharoptosis to 2.6 points and 2.3 points, respectively, while decreasing hypothermia[1].
Azaphen (25-50 mg/kg; s.c.; single dose) antagonizes Tetrabenazine (HY-B0590)-induced depression effects in white mice, reducing blepharoptosis to 2.3 points and 1.1 points, respectively, while decreasing hypothermia and catalepsy[1].
Azaphen (25 mg/kg; p.o.; single dose) significantly increases active escape attempts in the mouse water escape test, with a mean of 48 water wheel rotations per mouse over 6 minutes[2].
Azaphen (10-25 mg/kg; p.o.; single dose) exhibits antireserpine activity in mice, with a statistically significant reduction in Reserpine-induced blepharoptosis at 25 mg/kg to a rate of 2.7[2].
Azaphen (25 mg/kg; p.o.; single dose) significantly reduces anxiety-related inhibition in mice exposed to electric irritation, increasing plate crossings to 10.5 over 2 minutes[2].
Azaphen (25 mg/kg; p.o.; single dose) significantly reduces aggressive behavior in mice, decreasing fight counts to 8 (isolation-induced) and 9 (electric irritation-induced)[2].
Azaphen (10 mg/kg; p.o.; single dose) significantly reduces amnesia in rats, increasing passive avoidance conditioned reflex retention to 30% (electroshock-induced) and 50% (Scopolamine (HY-N0296)-induced)[2].
Azaphen (10 mg/kg; p.o.; daily; 4 days) does not produce a statistically significant restoration of ethanol-impaired active avoidance conditioned reflex learning in rats[2].
Azaphen (25-100 mg/kg; p.o.; single dose) exhibits dose-dependent antihypoxic activity in mice, significantly increasing survival time in hypoxic hypoxia at 50 mg/kg (37 min) and 100 mg/kg (44 min), and in hemic hypoxia at 25 mg/kg (22 min) and 50 mg/kg (21 min)[2].
Azaphen (25 mg/kg; p.o.; daily; 5 days) produces a pronounced protective effect in rats with circulatory hypoxia, resulting in 100% survival over 5 days[2].
Azaphen (5-25 mg/kg; p.o.; single dose) increases physical endurance in mice swimming with a load[2].
Azaphen (25 mg/kg; p.o.; single dose) does not produce a statistically significant change in mouse motor activity[2].
Azaphen (25-50 mg/kg; s.c.; single dose) significantly increases the group toxicity of Phenamine in white mice, inducing up to 95% mortality when combined with 10 mg/kg Phenamine, while also enhancing Phenamine-induced motor activity and hyperthermia[1].
Azaphen (25-50 mg/kg; s.c.; single dose) antagonizes Reserpine (HY-N0480)-induced depression effects in white mice, reducing blepharoptosis to 2.6 points and 2.3 points, respectively, while decreasing hypothermia[1].
Azaphen (25-50 mg/kg; s.c.; single dose) antagonizes Tetrabenazine (HY-B0590)-induced depression effects in white mice, reducing blepharoptosis to 2.3 points and 1.1 points, respectively, while decreasing hypothermia and catalepsy[1].
Azaphen (25 mg/kg; p.o.; single dose) significantly increases active escape attempts in the mouse water escape test, with a mean of 48 water wheel rotations per mouse over 6 minutes[2].
Azaphen (10-25 mg/kg; p.o.; single dose) exhibits antireserpine activity in mice, with a statistically significant reduction in Reserpine-induced blepharoptosis at 25 mg/kg to a rate of 2.7[2].
Azaphen (25 mg/kg; p.o.; single dose) significantly reduces anxiety-related inhibition in mice exposed to electric irritation, increasing plate crossings to 10.5 over 2 minutes[2].
Azaphen (25 mg/kg; p.o.; single dose) significantly reduces aggressive behavior in mice, decreasing fight counts to 8 (isolation-induced) and 9 (electric irritation-induced)[2].
Azaphen (10 mg/kg; p.o.; single dose) significantly reduces amnesia in rats, increasing passive avoidance conditioned reflex retention to 30% (electroshock-induced) and 50% (Scopolamine (HY-N0296)-induced)[2].
Azaphen (10 mg/kg; p.o.; daily; 4 days) does not produce a statistically significant restoration of ethanol-impaired active avoidance conditioned reflex learning in rats[2].
Azaphen (25-100 mg/kg; p.o.; single dose) exhibits dose-dependent antihypoxic activity in mice, significantly increasing survival time in hypoxic hypoxia at 50 mg/kg (37 min) and 100 mg/kg (44 min), and in hemic hypoxia at 25 mg/kg (22 min) and 50 mg/kg (21 min)[2].
Azaphen (25 mg/kg; p.o.; daily; 5 days) produces a pronounced protective effect in rats with circulatory hypoxia, resulting in 100% survival over 5 days[2].
Azaphen (5-25 mg/kg; p.o.; single dose) increases physical endurance in mice swimming with a load[2].
Azaphen (25 mg/kg; p.o.; single dose) does not produce a statistically significant change in mouse motor activity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:White mice[1]
-
Dosage:25 mg/kg; 50 mg/kg
-
Administration:s.c.; single dose
-
Result:Caused 35% mortality when combined with Phenamine (5 mg/kg).
Caused 65% mortality when combined with Phenamine (5 mg/kg).
Caused 60% mortality when combined with Phenamine (10 mg/kg).
Caused 95% mortality when combined with Phenamine (10 mg/kg).
Enhanced Phenamine-induced motor activity and hyperthermia.
-
Animal Model:White mice[1]
-
Dosage:25 mg/kg; 50 mg/kg
-
Administration:s.c.; single dose
-
Result:Reduced Tetrabenazine-induced blepharoptosis from a control of 3.2 points to 2.3 points.
Reduced Tetrabenazine-induced blepharoptosis from a control of 3.2 points to 1.1 points.
Decreased Tetrabenazine-induced hypothermia and catalepsy.
-
Animal Model:White mice[1]
-
Dosage:25 mg/kg; 50 mg/kg
-
Administration:s.c.; single dose
-
Result:Reduced Tetrabenazine-induced blepharoptosis from a control of 3.2 points to 2.3 points.
Reduced Tetrabenazine-induced blepharoptosis from a control of 3.2 points to 1.1 points.
Decreased Tetrabenazine-induced hypothermia and catalepsy.
-
Animal Model:white mice (male and female, 18-20 g)[2]
-
Dosage:25 mg/kg
-
Administration:p.o.; single dose
-
Result:Increased the number of water wheel rotations to 48 per mouse.
-
Animal Model:white mice (male and female, 18-20 g)[2]
-
Dosage:10 mg/kg; 25 mg/kg
-
Administration:p.o.; single dose
-
Result:Resulted in a blepharoptosis rate of 3.0 per mouse at 10 mg/kg.
Resulted in a blepharoptosis rate of 2.7 per mouse at 25 mg/kg, which was statistically significant compared to control.
-
Animal Model:white mice (male and female, 18-20 g)[2]
-
Dosage:25 mg/kg
-
Administration:p.o.; single dose
-
Result:Increased the number of plate crossings to 10.5 per mouse, a statistically significant increase compared to the irritated control group.
-
Animal Model:white mice (male and female, 18-20 g)[2]
-
Dosage:25 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced the number of fights to 8 in isolation-induced aggression, statistically significant compared to control.
Reduced the number of fights to 9 in electric irritation-induced aggression, statistically significant compared to control.
-
Animal Model:white mongrel rats (male, 180-200 g)[2]
-
Dosage:10 mg/kg
-
Administration:p.o.; single dose
-
Result:Increased the percentage of rats retaining PACR from 3% to 30% in electroshock-induced amnesia, statistically significant compared to control.
Increased the percentage of rats retaining PACR from 20% to 50% in Scopolamine-induced amnesia, statistically significant compared to control.
-
Animal Model:white mongrel rats (male, 180-200 g)[2]
-
Dosage:10 mg/kg
-
Administration:p.o.; daily; 4 days
-
Result:Resulted in 2, 7, 13, and 14 AACR events over 10 runs in 10 rats on days 1-4 of training, with no statistically significant difference compared to the ethanol-only control group.
-
Animal Model:white mice (male and female, 18-20 g)[2]
-
Dosage:25 mg/kg; 50 mg/kg; 100 mg/kg
-
Administration:p.o.; single dose
-
Result:Increased survival time to 34 min in hypoxic hypoxia at 25 mg/kg.
Increased survival time to 37 min in hypoxic hypoxia at 50 mg/kg, statistically significant.
Increased survival time to 44 min in hypoxic hypoxia at 100 mg/kg, statistically significant.
Increased survival time to 22 min in hemic hypoxia at 25 mg/kg, statistically significant.
Increased survival time to 21 min in hemic hypoxia at 50 mg/kg, statistically significant.
-
Animal Model:white mongrel rats (male, 180-200 g)[2]
-
Dosage:25 mg/kg
-
Administration:p.o.; daily; 5 days
-
Result:Resulted in 100% survival on both day 1 and day 5 post-ligation, a statistically significant increase compared to control.
-
Animal Model:white mice (male and female, 18-20 g)[2]
-
Dosage:5 mg/kg; 10 mg/kg; 25 mg/kg
-
Administration:p.o.; single dose
-
Result:Increased swimming duration to 8.3 min at 5 mg/kg, statistically significant.
Increased swimming duration to 11.8 min at 10 mg/kg, statistically significant.
Increased swimming duration to 12.1 min at 25 mg/kg, statistically significant.
-
Animal Model:white mice[2]
-
Dosage:25 mg/kg
-
Administration:p.o.; single dose
-
Result:Resulted in 508 runs per group of 3 mice, with no statistically significant difference compared to control.
Chemical Information
-
CAS No. 24853-80-3
-
Molecular Weight 370.28
-
Formula C16H21Cl2N5O
-
SMILES
[H]Cl.[H]Cl.CN1C2=CC=CC=C2OC3=C1C=C(N4CCN(C)CC4)N=N3
-
Synonyms
Azafen; Pipofezin hydrochloride; Pipofezine hydrochloride
-
Structure Classification
-
Initial Source
from the cadaveric material
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
All
Journal Impact Factor
-
Journal Impact Factor
-
Most Recent
-
Biochim Biophys Acta Gen Subj
5-Hydroxytryptamine activates a 5-HT/c-Myc/SLC6A4 signaling loop in non-small cell lung cancer. [Abstract]2022 Apr;1866(4):130093. PMID: 35066124
Purity & Documentation
Select Batch:
Purity:
99.98%
Assay:
99.98%
ee.:
99.98%
References
Calculators
Molarity Calculator
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
=
×
×
Dilution Calculator
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Azaphen Related Classifications
HY-A0022 Related Classifications
Powered by Bioz